Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

XTRA:JUN3
XTRA:JUN3Machinery

AntOn Value Launch in Asia-Pacific Might Change The Case For Investing In Jungheinrich (XTRA:JUN3)

Jungheinrich has launched "AntOn by Jungheinrich" in the Asia-Pacific region, introducing a value-focused brand offering lithium-ion forklift trucks and a pallet truck as the first step toward a broader material handling range. This new brand extends Jungheinrich’s portfolio into the value segment of Asia-Pacific material handling, aligning with its Strategy 2030+ and targeting customers prioritizing cost-effective reliability. We will now examine how this Asia-Pacific launch of a...
NasdaqGS:REYN
NasdaqGS:REYNHousehold Products

Is Reynolds Consumer Products (REYN) Still Attractive After Recent Share Price Stability

Investors may be wondering if Reynolds Consumer Products, at around US$24.28 a share, still offers solid value or if most of the opportunity is already reflected in the price. Over the short term, the stock has been fairly steady, with a 0.2% decline over 7 days, a 3.1% gain over 30 days, and a 5.3% return year to date. The 1 year return sits at an 8.7% decline, and the 3 and 5 year returns are 8.2% and 8.9% declines respectively. Recent attention on household and consumer staples companies...
ASX:COH
ASX:COHMedical Equipment

Cochlear Valuation Check As Nucleus Nexa System Reaches US Veterans Through VA Clinics

What Cochlear’s VA access milestone could mean for shareholders Cochlear (ASX:COH) has flagged a new chapter for its flagship Nucleus Nexa System. The device is now available to eligible US military veterans through VA clinics nationwide, opening an additional access point in a key healthcare channel. See our latest analysis for Cochlear. While Cochlear’s A$270.22 share price has seen a 3.44% 1 month share price return, the 90 day share price return of 7.24% and 1 year total shareholder...
BME:MAP
BME:MAPInsurance

Does UBS’s Downgrade Recast Mapfre (BME:MAP) As A Value Trap Or An Overlooked Insurer?

In recent days, UBS issued a sell rating on Spanish insurer Mapfre, while assigning a buy rating to its peer Linea Directa. This contrasting analyst stance comes as Mapfre showed relative resilience on a weak Spanish equity market day, drawing extra investor attention. We will now examine how UBS’s bearish stance shapes Mapfre’s investment narrative and what it might mean for investor perception. Uncover the next big thing with financially sound penny stocks that balance risk and reward.What...
SEHK:290
SEHK:290Capital Markets

Assessing GoFintech Quantum Innovation (SEHK:290) Valuation After Postponed Artwork Acquisition Circular

Event driven shift and why it matters for investors GoFintech Quantum Innovation (SEHK:290) has postponed its shareholder circular for a large artwork acquisition, with the document now expected by 20 February 2026. This extends the timetable for investor approval of this diversification move. See our latest analysis for GoFintech Quantum Innovation. The postponed circular comes after a very strong recent run in the shares, with a 30 day share price return of 16.41%, a 90 day return of...
XTRA:SY1
XTRA:SY1Chemicals

Large Non‑Cash Impairments And Portfolio Moves Might Change The Case For Investing In Symrise (XTRA:SY1)

Symrise AG has recorded non-cash impairment charges of about €145 million on its terpenes business and €150 million on its investment in Swedencare AB, both booked in the fourth quarter of 2025 and linked to a planned sale process and application of IFRS 5. The company also plans to present at the 25th German Corporate Conference in Frankfurt, giving management an opportunity to explain how these impairments and portfolio moves affect its financial profile and business focus. Next, we’ll...
LSE:HFG
LSE:HFGFood

dotdigital Group Leads The Charge In UK Penny Stocks

The United Kingdom's stock market has recently faced challenges, with the FTSE 100 and FTSE 250 indices experiencing declines amid weak trade data from China, impacting sectors closely tied to global economic trends. Despite these broader market pressures, there remains an intriguing segment of the market that investors often overlook: penny stocks. Although the term may seem outdated, it still denotes smaller or newer companies that can offer substantial value when backed by strong...
NYSE:MUR
NYSE:MUROil and Gas

Murphy Oil Reassesses Côte D'Ivoire After Civette Setback And New Prospects

Murphy Oil (NYSE:MUR) reported that its Civette-1X exploration well offshore Côte d'Ivoire encountered non-commercial hydrocarbons. The result, in Block CI-502, was announced as an early-stage outcome that will inform the company's international exploration efforts. Murphy Oil plans to focus next on the nearby Caracal and Bubale prospects in the same offshore area. Murphy Oil, an independent exploration and production company, is using this early result from Civette-1X as a data point for...
ASX:VAU
ASX:VAUMetals and Mining

Why Vault Minerals (ASX:VAU) Is Up 7.3% After Reaffirming FY26 Guidance And Project Timelines – And What's Next

Vault Minerals recently reported its December 2025 quarter, delivering 76,520 ounces of gold and generating A$12,000,000 in free cash flow while advancing major growth projects including the Stage 1 King of the Hills processing plant expansion and the Deflector mine transition to owner-operator mining. The company’s reiteration of FY26 group production guidance of 332,000 to 360,000 ounces and its articulated pathway to higher output by FY28 underline a clear operational roadmap that may...
NYSE:SFBS
NYSE:SFBSBanks

ServisFirst Bancshares Q4 Net Interest Margin Strengthens Bullish Narratives On Profitability

ServisFirst Bancshares (SFBS) capped FY 2025 with fourth quarter revenue of US$154.3 million and EPS of US$1.58, as trailing twelve month figures reached US$527.1 million in revenue and EPS of US$5.06. Over the past year, revenue has moved from US$458.7 million on a trailing basis to US$527.1 million, while EPS over the same period shifted from US$4.17 to US$5.06, providing additional context for how you might think about the bank’s earnings power. With a trailing net profit margin of 52.5%...
NYSE:SCHW
NYSE:SCHWCapital Markets

Schwab (SCHW) Margin Expansion Reinforces Bullish Narratives Despite Modest Revenue Growth

Charles Schwab FY 2025 Earnings Snapshot Charles Schwab (SCHW) closed FY 2025 with fourth quarter revenue of US$6.3 billion and basic EPS of US$1.34, alongside net income excluding extra items of US$2.4 billion, putting a solid set of headline numbers in front of investors. The company has seen quarterly revenue move from US$5.3 billion and EPS of US$0.94 in Q4 2024 to US$6.3 billion and EPS of US$1.34 in Q4 2025, alongside trailing twelve month EPS of US$4.67 and revenue of US$24.0 billion...
NasdaqGM:ATRC
NasdaqGM:ATRCMedical Equipment

AtriCure (ATRC) Is Up 5.1% After Raising 2026 Guidance And Refinancing Credit Facility - Has The Bull Case Changed?

Earlier in January 2026, AtriCure issued 2026 revenue guidance of approximately US$600 million to US$610 million and amended its asset-based revolving credit facility, extending the term, lowering interest rates and maintaining up to US$125 million in borrowing capacity with the option to increase to US$165 million. Together, the higher revenue outlook and more flexible, lower-cost credit line highlight management’s confidence in AtriCure’s growth plans and liquidity position. Next, we’ll...
NasdaqGS:UAL
NasdaqGS:UALAirlines

United Airlines Holdings UAL Q4 EPS Beat Tests Bearish Margin Concerns

United Airlines FY 2025 Earnings Snapshot United Airlines Holdings (UAL) has wrapped up FY 2025 with Q4 revenue of US$15.4b and basic EPS of US$3.19, supported by net income of US$1,044m. Over recent quarters, the company has seen revenue move from US$14.7b in Q4 2024 to US$15.2b in Q3 2025 and US$15.4b in Q4 2025. Basic EPS over the same Q4 periods shifted from US$2.94 to US$3.19, setting up a results season where investors can weigh steady top line and earnings against how efficiently those...
NasdaqGS:DAWN
NasdaqGS:DAWNBiotechs

Assessing Day One Biopharmaceuticals (DAWN) Valuation After Strong OJEMDA Revenue Update And 2026 Growth Outlook

Why Day One Biopharmaceuticals is in the spotlight Day One Biopharmaceuticals (DAWN) is back on investors’ radar after releasing preliminary 2025 OJEMDA revenue figures and issuing fresh 2026 guidance that ties directly to prescription and patient demand trends. The company reported unaudited OJEMDA net product revenue of approximately US$52.8 million for the fourth quarter of 2025 and US$155.4 million for the full year, with prescription volumes reaching 1,394 in the quarter. Management also...
NYSE:ST
NYSE:STElectrical

Should Sensata’s New STEV High‑Voltage Contactors Reshape the EV Narrative for Sensata Technologies (ST) Investors?

In mid-January 2026, Sensata Technologies announced the launch of its STEV high-voltage contactor series, a scalable, customizable solution designed to improve safety, efficiency and integration across battery electric and plug-in hybrid vehicle platforms from passenger cars to heavy-duty trucks. A distinctive aspect of the STEV lineup is its combination of bidirectional current capability, hermetic ceramic sealing and global in-region manufacturing, positioning Sensata as a key enabler of...
NYSE:TDY
NYSE:TDYElectronic

Teledyne Technologies Q4 EPS Strength Tests Slower Growth Narratives

Teledyne Technologies (TDY) has wrapped up FY 2025 with fourth quarter revenue of US$1.6b and basic EPS of US$5.60, alongside trailing twelve month revenue of US$6.1b and EPS of US$18.88 that frame the latest print in a broader earnings run. Over the past six quarters in the data, quarterly revenue has ranged from US$1.44b to US$1.61b, while basic EPS has moved between US$4.03 and US$5.61, giving investors a clear view of how the top and bottom lines have tracked together through recent...
NYSE:UTI
NYSE:UTIConsumer Services

Is It Too Late To Consider Universal Technical Institute (UTI) After Strong Multi‑Year Share Gains?

If you are wondering whether Universal Technical Institute's share price still offers value after recent moves, it helps to step back and look at what the current market price might be implying. The stock last closed at US$28.15, with returns of 5.9% over the past week, 5.0% over the last month, 13.3% year to date, 6.1% over 1 year, and very large gains over 3 and 5 years. Recent attention on Universal Technical Institute has focused on its role in career and technical education, as...
NasdaqGM:IRMD
NasdaqGM:IRMDMedical Equipment

How Record Q3 Results And FDA-Cleared MRI Pump Launch At IRADIMED (IRMD) Has Changed Its Investment Story

Riverwater Partners recently highlighted IRADIMED CORPORATION as the top contributor to its Micro Opportunities Strategy in 2025, following record Q3 2025 revenue of US$21.2 million and FDA approval of the company’s MRI-compatible 3870 IV infusion pump in July 2025. Beyond the financial headlines, IRADIMED’s combination of accelerating revenue, new FDA-cleared technology and a special dividend, alongside insider share sales and a “Moderate Buy” analyst consensus, paints a complex picture of...
TSX:GIL
TSX:GILLuxury

TSX Stocks Estimated Below Fair Value In January 2026

As the Canadian market navigates a landscape filled with geopolitical tensions and U.S. policy shifts, fundamentals such as low energy prices, moderating inflation, and solid growth continue to underpin its stability. In this environment of broadening market leadership and resilience, identifying stocks that are trading below their fair value can offer potential opportunities for investors focused on strong economic and corporate fundamentals.